Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL. Sasaki K, Yamauchi T, Semba Y, Nogami J, et al. Blood 2022;139:748-760.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sasaki K, Yamauchi T, Semba Y, Nogami J, et al. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL. Blood 2022;139:748-760.
PMID: 34587248